Published in CMAJ on September 16, 2003
Impact of Pharmacotherapy Management in Patients With Alzheimer's Disease | NCT02222181
Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. Clin Interv Aging (2008) 1.72
Have last-observation-carried-forward analyses caused us to favour more toxic dementia therapies over less toxic alternatives? A systematic review. Open Med (2009) 1.62
Does analysis using "last observation carried forward" introduce bias in dementia research? CMAJ (2008) 1.31
Patient and caregiver quality of life in Huntington's disease. Mov Disord (2008) 1.29
Vascular disease and dementias: paradigm shifts to drive research in new directions. Alzheimers Dement (2012) 1.21
Diagnosis and treatment of dementia: 5. Nonpharmacologic and pharmacologic therapy for mild to moderate dementia. CMAJ (2008) 1.15
Update on the pharmacological treatment of Alzheimer's disease. Curr Neuropharmacol (2010) 1.07
Dual use of bladder anticholinergics and cholinesterase inhibitors: long-term functional and cognitive outcomes. J Am Geriatr Soc (2008) 1.07
Ablation of TNF-RI/RII expression in Alzheimer's disease mice leads to an unexpected enhancement of pathology: implications for chronic pan-TNF-α suppressive therapeutic strategies in the brain. Am J Pathol (2011) 1.02
Alzheimer's therapeutics: translation of preclinical science to clinical drug development. Neuropsychopharmacology (2011) 1.02
Sufficiently important difference for common cold: severity reduction. Ann Fam Med (2007) 1.01
Progress update: Pharmacological treatment of Alzheimer's disease. Neuropsychiatr Dis Treat (2007) 0.96
A cohort study of effectiveness of acetylcholinesterase inhibitors in Alzheimer's disease. Eur J Clin Pharmacol (2005) 0.94
Treatment guidelines for Alzheimer's disease: redefining perceptions in primary care. Prim Care Companion J Clin Psychiatry (2007) 0.92
Positive allosteric modulator of α7 nicotinic-acetylcholine receptors, PNU-120596 augments the effects of donepezil on learning and memory in aged rodents and non-human primates. Neuropharmacology (2012) 0.90
Prescribing patterns for Alzheimer disease: survey of Canadian family physicians. Can Fam Physician (2006) 0.89
The neurotrophic compound J147 reverses cognitive impairment in aged Alzheimer's disease mice. Alzheimers Res Ther (2013) 0.88
The ethics of elective psychopharmacology. Int J Neuropsychopharmacol (2011) 0.85
Concepts for the treatment of Alzheimer's disease: molecular mechanisms and clinical application. Int J Exp Pathol (2005) 0.85
Therapy for Alzheimer's Disease: How Effective are Current Treatments? Ther Adv Neurol Disord (2009) 0.85
(+)-Arisugacin A--computational evidence of a dual binding site covalent inhibitor of acetylcholinesterase. Bioorg Med Chem Lett (2010) 0.84
To treat or not to treat? A meta-analysis of the use of cholinesterase inhibitors in mild cognitive impairment for delaying progression to Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci (2009) 0.83
Effectiveness and Safety of MLC601 in the Treatment of Mild to Moderate Alzheimer's Disease: A Multicenter, Randomized Controlled Trial. Dement Geriatr Cogn Dis Extra (2015) 0.83
Population pharmacokinetic approach to evaluate the effect of CYP2D6, CYP3A, ABCB1, POR and NR1I2 genotypes on donepezil clearance. Br J Clin Pharmacol (2014) 0.83
Comparison of persistence rates of acetylcholine-esterase inhibitors in a state Medicaid program. Patient Prefer Adherence (2008) 0.82
Potential cognitive enhancing and disease modification effects of SSRIs for Alzheimer's disease. Neuropsychiatr Dis Treat (2007) 0.82
Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics. Neuropsychiatr Dis Treat (2007) 0.82
Treatment effects in multiple cognitive domains in Alzheimer's disease: a two-year cohort study. Alzheimers Res Ther (2014) 0.81
Cholinesterase inhibitors: drugs looking for a disease? PLoS Med (2006) 0.80
Unraveling Alzheimer's: Making Sense of the Relationship between Diabetes and Alzheimer's Disease1. J Alzheimers Dis (2016) 0.79
Cholinesterase inhibitors in Alzheimer's disease and Lewy body spectrum disorders: the emerging pharmacogenetic story. Hum Genomics (2009) 0.79
Effect Size Analyses of Souvenaid in Patients with Alzheimer's Disease. J Alzheimers Dis (2016) 0.78
Relations between cognitive status and medication adherence in patients treated for memory disorders. Ageing Res (2012) 0.78
Adding memantine to rivastigmine therapy in patients with mild-to-moderate alzheimer's disease: results of a 12-week, open-label pilot study. Prim Care Companion J Clin Psychiatry (2006) 0.78
Rivastigmine in Alzheimer's disease: Cognitive function and quality of life. Ther Clin Risk Manag (2007) 0.77
Donepezil reverses nicotine withdrawal-induced deficits in contextual fear conditioning in C57BL/6J mice. Behav Neurosci (2014) 0.77
Rapid neurobehavioural analysis based on the effects of an acetylcholinesterase inhibitor from Tephrosia purpurea in Zebrafish. Ann Neurosci (2012) 0.75
Development of a self-administered web-based test for longitudinal cognitive assessment. Sci Rep (2016) 0.75
Time related effects on functional brain connectivity after serotonergic and cholinergic neuromodulation. Hum Brain Mapp (2016) 0.75
Are there long-term benefits of donepezil in Alzheimer's disease? CMAJ (2004) 0.75
Nonpatentable drugs and the cost of our ignorance. CMAJ (2006) 0.75
Substitute consent for research involving the elderly: a comparison between Quebec and France. J Cross Cult Gerontol (2008) 0.75
Dementia. BMJ Clin Evid (2010) 0.75
Short and Long-term Effects of rTMS Treatment on Alzheimer's Disease at Different Stages: A Pilot Study. J Exp Neurosci (2015) 0.75
Psychotropic medication use in canadian long-term care patients referred for psychogeriatric consultation. Can Geriatr J (2011) 0.75
Drug therapy for Alzheimer's disease. CMAJ (2004) 0.75
Risk of pneumonia associated with incident benzodiazepine use among community-dwelling adults with Alzheimer disease. CMAJ (2017) 0.75
Drug therapy for Alzheimer's disease. CMAJ (2004) 0.75
A computational view on the significance of E-ring in binding of (+)-arisugacin A to acetylcholinesterase. Bioorg Med Chem Lett (2015) 0.75
Older patients are still under-represented in clinical trials of Alzheimer's disease. Alzheimers Res Ther (2016) 0.75
Risk Factors for Progression of Alzheimer Disease in a Canadian Population: The Canadian Outcomes Study in Dementia (COSID). Can J Psychiatry (2015) 0.75
Effects of acute administration of donepezil or memantine on sleep-deprivation-induced spatial memory deficit in young and aged non-human primate grey mouse lemurs (Microcebus murinus). PLoS One (2017) 0.75
Discontinuation, efficacy and safety of cholinesterase inhibitors for Alzheimer's disease: a meta-analysis and meta-regression of 44 randomized clinical trials enrolling 16,245 patients. Int J Neuropsychopharmacol (2017) 0.75
Meta-analysis in clinical trials. Control Clin Trials (1986) 144.91
Bias in meta-analysis detected by a simple, graphical test. BMJ (1997) 122.24
Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology (1984) 119.59
Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials (1996) 64.38
Operating characteristics of a rank correlation test for publication bias. Biometrics (1994) 47.97
Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet (1998) 19.31
A new rating scale for Alzheimer's disease. Am J Psychiatry (1984) 15.16
The number needed to treat: a clinically useful measure of treatment effect. BMJ (1995) 13.89
Confidence intervals for the number needed to treat. BMJ (1998) 9.59
Meta-analysis: state-of-the-science. Epidemiol Rev (1992) 8.91
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology (1998) 7.27
Canadian study of health and aging: study methods and prevalence of dementia. CMAJ (1994) 6.91
Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ (1999) 5.36
The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group. Dementia (1997) 5.31
Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA (2003) 5.23
Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet (2002) 5.05
Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med (1998) 4.43
The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry (1999) 3.98
Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord (1997) 3.77
Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2001) 3.74
A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology (2001) 3.25
A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc (2001) 3.20
Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study. Eur Neuropsychopharmacol (1998) 3.18
The recognition, assessment and management of dementing disorders: conclusions from the Canadian Consensus Conference on Dementia. CMAJ (1999) 3.14
Treatment of Alzheimer's disease. N Engl J Med (1999) 3.03
A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology (2000) 2.99
A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease. Int J Clin Pract (2002) 2.86
A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology (2001) 2.78
Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology (2000) 2.64
A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology (2001) 2.38
The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dement Geriatr Cogn Disord (1999) 2.30
The incidence of dementia in Canada. The Canadian Study of Health and Aging Working Group. Neurology (2000) 2.22
A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur Neurol (2000) 1.98
Donepezil therapy in clinical practice: a randomized crossover study. Arch Neurol (2000) 1.93
Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet (1995) 1.89
Apolipoprotein E polymorphism in health and disease. Am Heart J (1987) 1.84
Pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy male volunteers. Int J Clin Pharmacol Ther Toxicol (1993) 1.79
Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol (2001) 1.62
Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group. Dement Geriatr Cogn Disord (2001) 1.59
Interrater reliability of the modified Jadad quality scale for systematic reviews of Alzheimer's disease drug trials. Dement Geriatr Cogn Disord (2001) 1.55
Pharmacokinetic and pharmacodynamic profile of donepezil HCl following multiple oral doses. Br J Clin Pharmacol (1998) 1.53
Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial. J Neurol Neurosurg Psychiatry (2001) 1.44
Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol (2000) 1.36
Canadian Consensus Conference on Dementia: a physician's guide to using the recommendations. CMAJ (1999) 1.34
Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease. Int J Geriatr Psychiatry (2001) 1.31
Pharmacokinetic and pharmacodynamic profile of donepezil HCl following single oral doses. Br J Clin Pharmacol (1998) 1.29
The Clinician Interview-Based Impression (CIBI): a clinician's global change rating scale in Alzheimer's disease. Neurology (1994) 1.27
The recognition, assessment and management of dementing disorders: conclusions from the Canadian Consensus Conference on Dementia. Can J Neurol Sci (2001) 1.27
Is donepezil effective for treating Alzheimer's disease? Can Fam Physician (1999) 1.09
A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon). Eur J Neurol (1999) 1.09
Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease. Int J Neuropsychopharmacol (2001) 1.08
Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition. Eur Neurol (2002) 1.08
Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's disease. Life Sci (1996) 1.06
Cholinesterase inhibitors: a therapeutic strategy for Alzheimer disease. Ann Pharmacother (1999) 1.06
Do we have drugs for dementia? No. Arch Neurol (1999) 1.03
An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. Eur J Neurol (2000) 1.03
Cost-minimization and the number needed to treat in uncomplicated hypertension. Am J Hypertens (1998) 1.02
Donepezil hydrochloride preserves regional cerebral blood flow in patients with Alzheimer's disease. J Nucl Med (2001) 1.01
Neurological cholinesterases in the normal brain and in Alzheimer's disease: relationship to plaques, tangles, and patterns of selective vulnerability. Ann Neurol (1993) 1.01
Galantamine: a review of its use in Alzheimer's disease. Drugs (2000) 0.99
Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. Arch Neurol (2001) 0.96
A method for meta-analysis of epidemiological studies. Drug Intell Clin Pharm (1988) 0.93
Rivastigmine, a brain-region selective acetylcholinesterase inhibitor for treating Alzheimer's disease: review and current status. Expert Opin Investig Drugs (1999) 0.92
Invited review: Cholinesterase inhibitors for Alzheimer's disease therapy: from tacrine to future applications. Neurochem Int (1998) 0.91
Donepezil, rivastigmine, and vitamin E in Alzheimer disease: a combined P300 event-related potentials/neuropsychologic evaluation over 6 months. Clin Neuropharmacol (2001) 0.90
Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease. Biol Psychiatry (2001) 0.90
Review of the acetylcholinesterase inhibitor galanthamine. Expert Opin Investig Drugs (2000) 0.89
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease--pilot study. Int J Geriatr Psychiatry (2002) 0.88
How useful are cholinesterase inhibitors in the treatment of Alzheimer's disease? A number needed to treat analysis. Int J Geriatr Psychiatry (2000) 0.88
Orbital and dorsolateral frontal perfusion defect associated with behavioral response to cholinesterase inhibitor therapy in Alzheimer's disease. J Neuropsychiatry Clin Neurosci (2000) 0.87
Effects of donepezil on emotional/behavioral symptoms in Alzheimer's disease patients. J Clin Psychiatry (2000) 0.86
Cholinergic neurotransmission, REM sleep and depression. J Psychosom Res (1994) 0.85
Amisulpride for schizophrenia. Cochrane Database Syst Rev (2002) 0.83
Donepezil. Drugs Aging (1997) 0.83
WITHDRAWN: Antidepressants for depression in medical illness. Cochrane Database Syst Rev (2007) 0.81
Protease inhibitors and indolamines selectively inhibit cholinesterases in the histopathologic structures of Alzheimer's disease. Ann N Y Acad Sci (1993) 0.81
Effects of the novel acetylcholinesterase inhibitor SDZ ENA 713 on sleep in man. Neuropsychopharmacology (1993) 0.80
The use of numbers needed to treat derived from systematic reviews and meta-analysis. Caveats and pitfalls. Eval Health Prof (2001) 0.79
Pharmacokinetic and other related factors affecting psychotropic responses in Asians. Psychopharmacol Bull (1991) 0.79
Cholinomimetic treatment of Alzheimer's disease. Prog Brain Res (1996) 0.77
A meta-analysis of cytokines in major depression. Biol Psychiatry (2009) 7.16
Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ (2005) 6.57
Prevalence of depression during pregnancy: systematic review. Obstet Gynecol (2004) 5.42
Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med (2007) 3.71
Antipsychotic drugs and hyperglycemia in older patients with diabetes. Arch Intern Med (2009) 3.43
Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol (2007) 3.22
Medical illness and the risk of suicide in the elderly. Arch Intern Med (2004) 3.09
Systematic review and meta-analysis of the effect of warming local anesthetics on injection pain. Ann Emerg Med (2011) 2.33
Effect of a perturbation-based balance training program on compensatory stepping and grasping reactions in older adults: a randomized controlled trial. Phys Ther (2010) 2.31
Zinc in depression: a meta-analysis. Biol Psychiatry (2013) 2.26
Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis. Clin Ther (2002) 2.18
A meta-analysis of cytokines in Alzheimer's disease. Biol Psychiatry (2010) 2.06
The safety of proton pump inhibitors (PPIs) in pregnancy: a meta-analysis. Am J Gastroenterol (2009) 2.03
Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy. Am J Psychiatry (2008) 2.01
Contribution of informant and patient ratings to the accuracy of the mini-mental state examination in predicting probable Alzheimer's disease. J Am Geriatr Soc (2003) 1.93
Sensitivity of patient outcomes to pharmacist interventions. Part II: Systematic review and meta-analysis in hypertension management. Ann Pharmacother (2007) 1.90
Functional neuroanatomical substrates of altered reward processing in major depressive disorder revealed by a dopaminergic probe. Arch Gen Psychiatry (2005) 1.85
Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ (2005) 1.84
Benzodiazepine use and driving: a meta-analysis. J Clin Psychiatry (2009) 1.81
Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology (2010) 1.80
Rates of spontaneous and therapeutic abortions following use of antidepressants in pregnancy: results from a large prospective database. J Obstet Gynaecol Can (2009) 1.76
Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo-controlled trial. J Clin Psychiatry (2013) 1.73
Efficacy and safety of antidepressants for treatment of depression in Alzheimer's disease: a metaanalysis. Can J Psychiatry (2007) 1.72
Sensitivity of patient outcomes to pharmacist interventions. Part I: systematic review and meta-analysis in diabetes management. Ann Pharmacother (2007) 1.64
Neuropsychiatric symptoms in Alzheimer's disease: past progress and anticipation of the future. Alzheimers Dement (2013) 1.51
Clinical and cost implications of target joints in Canadian boys with severe hemophilia A. J Pediatr (2004) 1.50
Collaborative medication management in a team-based primary care practice: an explanatory conceptual framework. Res Social Adm Pharm (2005) 1.50
Sensitivity of patient outcomes to pharmacist interventions. Part III: systematic review and meta-analysis in hyperlipidemia management. Ann Pharmacother (2008) 1.48
Patterns of paediatric analgesic use in Africa: a systematic review. Arch Dis Child (2012) 1.42
Recommendations of the 4th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD4). Can Geriatr J (2012) 1.39
Treatments for metastatic melanoma: synthesis of evidence from randomized trials. Cancer Treat Rev (2007) 1.37
Effect of regulatory warnings on antipsychotic prescription rates among elderly patients with dementia: a population-based time-series analysis. CMAJ (2008) 1.34
Old and homeless: a review and survey of older adults who use shelters in an urban setting. Can J Psychiatry (2003) 1.30
Probing brain reward system function in major depressive disorder: altered response to dextroamphetamine. Arch Gen Psychiatry (2002) 1.26
IPA survey of brief cognitive screening instruments. Int Psychogeriatr (2006) 1.26
Malformation rates in children of women with untreated epilepsy: a meta-analysis. Drug Saf (2004) 1.21
Medicinal and recreational marijuana use by patients infected with HIV. AIDS Patient Care STDS (2004) 1.20
Increased use of antidepressants in Canada: 1981-2000. Ann Pharmacother (2002) 1.18
Depression during Pregnancy : Overview of Clinical Factors. Clin Drug Investig (2004) 1.18
Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev (2011) 1.18
Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. Curr Med Res Opin (2007) 1.17
Exposure to general anesthesia and risk of Alzheimer's disease: a systematic review and meta-analysis. BMC Geriatr (2011) 1.16
Use of complementary and alternative medicine by HIV-infected outpatients in Ontario, Canada. AIDS Patient Care STDS (2003) 1.14
Exposure to mirtazapine during pregnancy: a prospective, comparative study of birth outcomes. J Clin Psychiatry (2006) 1.13
Antidepressant use during pregnancy and the rates of spontaneous abortions: a meta-analysis. Ann Pharmacother (2005) 1.12
Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials. Curr Med Res Opin (2006) 1.12
Sharing the responsibility for assessing the risk of the driver with dementia. CMAJ (2007) 1.12
Intratympanic gentamicin for Menière's disease: a meta-analysis. Laryngoscope (2004) 1.10
Physiotherapy coupled with dextroamphetamine for rehabilitation after hemiparetic stroke: a randomized, double-blind, placebo-controlled trial. Stroke (2005) 1.08
Antidepressants, warfarin, and the risk of hemorrhage. J Clin Psychopharmacol (2005) 1.07
Reference values for hair cotinine as a biomarker of active and passive smoking in women of reproductive age, pregnant women, children, and neonates: systematic review and meta-analysis. Ther Drug Monit (2007) 1.06
Antipsychotic use in the elderly: shifting trends and increasing costs. Int J Geriatr Psychiatry (2005) 1.06
Mild cognitive impairment: an operational definition and its conversion rate to Alzheimer's disease. Dement Geriatr Cogn Disord (2005) 1.06
Initiation of benzodiazepines in the elderly after hospitalization. J Gen Intern Med (2007) 1.05
A perturbation-based balance training program for older adults: study protocol for a randomised controlled trial. BMC Geriatr (2007) 1.03
Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challenge. J Clin Psychopharmacol (2008) 1.02
Quality assessment of meta-analyses of RCTs of pharmacotherapy in major depressive disorder. Curr Med Res Opin (2004) 1.02
Incidence of major malformations in infants following antidepressant exposure in pregnancy: results of a large prospective cohort study. Can J Psychiatry (2009) 1.01
Pharmacological treatments for neuropsychiatric symptoms of dementia in long-term care: a systematic review. Int Psychogeriatr (2012) 1.01
The role of dopamine in symptoms and treatment of apathy in Alzheimer's disease. CNS Neurosci Ther (2010) 1.00
Effects of ω-3 fatty acids on cognitive performance: a meta-analysis. Neurobiol Aging (2012) 1.00
Mental health-related drug utilization among older adults: prevalence, trends, and costs. Am J Geriatr Psychiatry (2005) 0.99
The weekly cost of nausea and vomiting of pregnancy for women calling the Toronto Motherisk Program. Curr Med Res Opin (2007) 0.99
How much are atypical antipsychotic agents being used, and do they reach the populations who need them? A Canadian experience. Clin Ther (2002) 0.99
The role of norepinephrine in the behavioral and psychological symptoms of dementia. J Neuropsychiatry Clin Neurosci (2004) 0.99
Persistence and adherence with dementia pharmacotherapy: relevance of patient, provider, and system factors. Can J Psychiatry (2014) 0.98
Canadian Outcomes Study in Dementia: study methods and patient characteristics. Can J Psychiatry (2004) 0.98
The effects of lithium on renal function in older adults--a systematic review. J Geriatr Psychiatry Neurol (2012) 0.98
Management and prevention of diabetic foot ulcers and infections: a health economic review. Pharmacoeconomics (2008) 0.98
Adverse drug events in cognitively impaired elderly patients. Dement Geriatr Cogn Disord (2007) 0.98
The relationship between variations in antipsychotic prescribing across nursing homes and short-term mortality: quality of care implications. Med Care (2009) 0.98
Health state utilities and quality of life in patients with hepatitis B. Can J Gastroenterol (2012) 0.97
Meta-analysis of placebo rates in major depressive disorder trials. Ann Pharmacother (2003) 0.97
Economic burden of nausea and vomiting of pregnancy in the USA. J Popul Ther Clin Pharmacol (2013) 0.96
The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease. Expert Opin Drug Saf (2004) 0.96
GABAergic function in Alzheimer's disease: evidence for dysfunction and potential as a therapeutic target for the treatment of behavioural and psychological symptoms of dementia. Can J Psychiatry (2004) 0.96
Cost-of-illness study of type 2 diabetes mellitus in Colombia. Rev Panam Salud Publica (2009) 0.95
Relationship between hair cortisol concentrations and depressive symptoms in patients with coronary artery disease. Neuropsychiatr Dis Treat (2010) 0.95
Efficacy and feasibility of nonpharmacological interventions for neuropsychiatric symptoms of dementia in long term care: a systematic review. J Am Med Dir Assoc (2012) 0.95
A SPECT study of apathy in Alzheimer's disease. Dement Geriatr Cogn Disord (2007) 0.95
Statistics in the pharmacy literature. Ann Pharmacother (2004) 0.94
Advanced cutaneous malignant melanoma: a systematic review of economic and quality-of-life studies. Value Health (2008) 0.94
Comorbid depression and anxiety in later life: patterns of association, subjective well-being, and impairment. Am J Geriatr Psychiatry (2008) 0.93
Paternal organic solvent exposure and adverse pregnancy outcomes: a meta-analysis. Am J Ind Med (2005) 0.92
The relationship between inflammatory markers and post stroke cognitive impairment. J Geriatr Psychiatry Neurol (2010) 0.92
A system-wide analysis using a senior-friendly hospital framework identifies current practices and opportunities for improvement in the care of hospitalized older adults. J Am Geriatr Soc (2014) 0.91
Brain reward system activity in major depression and comorbid nicotine dependence. J Pharmacol Exp Ther (2002) 0.91
Verbal memory performance and completion of cardiac rehabilitation in patients with coronary artery disease. Psychosom Med (2011) 0.91
Systematic review and quality assessment of economic evaluations and quality-of-life studies related to generalized anxiety disorder. Clin Ther (2009) 0.91
Economic evaluation of Avonex (interferon beta-Ia) in patients following a single demyelinating event. Mult Scler (2005) 0.91
Interleukin-17 in post-stroke neurodegeneration. Neurosci Biobehav Rev (2013) 0.91
Electroconvulsive therapy in older adults: 13-year trends. Can J Psychiatry (2006) 0.90
Reducing fall risk by improving balance control: development, evaluation and knowledge-translation of new approaches. J Safety Res (2011) 0.89
Apathy associated with Alzheimer disease: use of dextroamphetamine challenge. Am J Geriatr Psychiatry (2008) 0.89
A randomized, placebo-controlled trial of the discontinuation of long-term antipsychotics in dementia. Int Psychogeriatr (2002) 0.89
Seroprevalence of Toxoplasma gondii infection among veterinary staff in Ontario, Canada (2002): implications for teratogenic risk. BMC Infect Dis (2003) 0.89
Outcome after traumatic brain injury sustained in older adulthood: a one-year longitudinal study. Am J Geriatr Psychiatry (2006) 0.89
Current place of monoamine oxidase inhibitors in the treatment of depression. CNS Drugs (2013) 0.89